DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Farther Finance Advisors LLC

Farther Finance Advisors LLC grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 29.3% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,100 shares of the medical device company’s stock after buying an additional 702 shares during the quarter. Farther Finance Advisors LLC’s holdings in DexCom were worth $209,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. Geode Capital Management LLC lifted its stake in DexCom by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company’s stock worth $775,256,000 after acquiring an additional 56,094 shares during the last quarter. Norges Bank acquired a new stake in shares of DexCom in the 4th quarter valued at $385,367,000. Northern Trust Corp raised its holdings in shares of DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company’s stock valued at $322,454,000 after purchasing an additional 753,857 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company’s stock worth $219,716,000 after purchasing an additional 91,051 shares during the last quarter. Finally, Artisan Partners Limited Partnership lifted its position in shares of DexCom by 12.2% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company’s stock worth $144,152,000 after purchasing an additional 201,181 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Down 1.0%

Shares of NASDAQ:DXCM opened at $81.01 on Friday. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $117.27. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. The stock has a market cap of $31.76 billion, a P/E ratio of 60.46, a P/E/G ratio of 1.73 and a beta of 1.46. The firm has a fifty day moving average price of $79.80 and a 200 day moving average price of $79.40.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the previous year, the company posted $0.32 earnings per share. DexCom’s quarterly revenue was up 12.5% on a year-over-year basis. Sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity

In other news, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the sale, the executive vice president now owns 109,621 shares of the company’s stock, valued at $9,329,843.31. The trade was a 5.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nicholas Augustinos sold 2,618 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $81.69, for a total transaction of $213,864.42. Following the transaction, the director now directly owns 37,083 shares of the company’s stock, valued at $3,029,310.27. This represents a 6.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 25,724 shares of company stock valued at $2,157,034. Company insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DXCM. Wall Street Zen raised DexCom from a “hold” rating to a “buy” rating in a report on Friday, June 6th. Cfra Research raised DexCom to a “hold” rating in a research report on Friday, March 21st. Piper Sandler dropped their price objective on DexCom from $100.00 to $90.00 and set an “overweight” rating on the stock in a report on Friday, May 2nd. Canaccord Genuity Group raised their target price on DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Finally, Robert W. Baird decreased their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $98.50.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.